Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 1,686 Cr.
- Current Price ₹ 38.5
- High / Low ₹ 65.3 / 11.7
- Stock P/E 63.0
- Book Value ₹
- Dividend Yield 0.03 %
- ROCE %
- ROE %
- Face Value ₹ 1.00
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 32.59 | |
| 19.87 | |
| Operating Profit | 12.72 |
| OPM % | 39.03% |
| 4.21 | |
| Interest | 0.59 |
| Depreciation | 3.00 |
| Profit before tax | 13.34 |
| Tax % | 28.19% |
| 9.58 | |
| EPS in Rs | 0.22 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 60% |
| 5 Years: | 186% |
| 3 Years: | 194% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
- Unaudited Financial Results For The Quarter Ended December 2025 3h
-
Board Meeting Outcome for Outcome Of The Meeting Of Board Held On Wednesday, February 04, 2026
3h - Q3 & nine-month unaudited: Total income ₹3,995.01L; Net profit ₹2,036.46L; MD re-appointed 30/12/2025–30/12/2030.
-
Update on board meeting
30 Jan - Board meeting 4 Feb 2026 to approve unaudited Q3 results for quarter ended 31 Dec 2025.
-
Board Meeting Intimation for Unaudited Financial Result For The Third Quarter Ended On 31 December, 2025 Along With The Auditor''s Limited Review Report.
30 Jan - Board meeting on 7 Feb 2026 to approve Q3 unaudited results (31 Dec 2025) and limited review report.
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Held On Today
28 Jan - Allotment of 4,643,000 warrants at Rs34; Rs3.94 crore received; balance Rs11.84 crore payable within 18 months.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies